---
figid: PMC5817855__12943_2018_804_Fig4_HTML
figtitle: Interruption of the BCR-Abl pathway can be achieved by Gleevec (imatinib
  mesylate)
organisms:
- NA
pmcid: PMC5817855
filename: 12943_2018_804_Fig4_HTML.jpg
figlink: /pmc/articles/PMC5817855/figure/Fig4/
number: F4
caption: Interruption of the BCR-Abl pathway can be achieved by Gleevec (imatinib
  mesylate)
papertitle: 'Kinase-targeted cancer therapies: progress, challenges and future directions.'
reftext: Khushwant S. Bhullar, et al. Mol Cancer. 2018;17:48.
year: '2018'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.7397942
figid_alias: PMC5817855__F4
figtype: Figure
organisms_ner:
- NA
redirect_from: /figures/PMC5817855__F4
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5817855__12943_2018_804_Fig4_HTML.html
  '@type': Dataset
  description: Interruption of the BCR-Abl pathway can be achieved by Gleevec (imatinib
    mesylate)
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Imatinib
  - ADP
  - ATP
---
